#1 Clinical Trials Search in Europe

REGN7544

REGN7544 is an experimental drug currently being studied in clinical trials for several conditions related to blood pressure regulation. This antagonist monoclonal antibody targets NPR1 (Natriuretic Peptide Receptor 1) and is being investigated for its potential to help patients with sepsis-induced hypotension, Postural Orthostatic Tachycardia Syndrome (POTS), and to understand its effects in healthy volunteers. These trials aim to evaluate the drug’s safety, effectiveness, and how it works in the body, providing valuable insights into a potential new treatment for conditions where blood pressure regulation is compromised.

Table of Contents

What is REGN7544?

REGN7544 is an investigational medication currently being studied in clinical trials. It is classified as an antagonist monoclonal antibody that targets a protein called NPR1 (Natriuretic Peptide Receptor 1)[1]. Monoclonal antibodies are laboratory-created proteins designed to target specific substances in the body. In this case, REGN7544 is designed to block the activity of NPR1, which plays a role in regulating blood pressure and heart function[2].

The drug is being developed and tested for different medical conditions that involve problems with blood pressure regulation. REGN7544 is not yet approved by regulatory agencies and is still considered experimental, meaning it is still being researched to determine if it is safe and effective for patient use[3].

How Does REGN7544 Work?

REGN7544 works by blocking (antagonizing) the NPR1 receptor. NPR1 is involved in the body’s natural process of regulating blood pressure. When certain hormones called natriuretic peptides bind to NPR1, they typically cause blood vessels to relax and widen, which can lower blood pressure[1].

By blocking NPR1, REGN7544 may help to prevent this blood pressure-lowering effect, which could be beneficial in conditions where blood pressure is too low or drops upon standing. This mechanism is particularly relevant for the conditions being studied in the clinical trials, including sepsis-induced hypotension (low blood pressure due to infection) and Postural Orthostatic Tachycardia Syndrome (POTS)[2].

Medical Conditions Being Studied

Sepsis-Induced Hypotension

One of the main conditions being studied with REGN7544 is sepsis-induced hypotension. Sepsis is a life-threatening condition that occurs when the body’s response to an infection damages its own tissues and organs. In sepsis, inflammation throughout the body can cause blood pressure to drop dangerously low (hypotension), which can lead to organ failure[1].

Currently, patients with sepsis-induced hypotension often require medications called vasopressors (drugs that constrict blood vessels to raise blood pressure) and intravenous fluids to maintain adequate blood pressure. Researchers are investigating whether REGN7544 could help improve blood pressure in these patients and potentially reduce the amount of vasopressor medication needed[1].

Postural Orthostatic Tachycardia Syndrome (POTS)

POTS is another condition being investigated for treatment with REGN7544. POTS is a disorder affecting circulation where a person’s heart rate increases abnormally when they stand up from a lying position. This is often accompanied by symptoms such as dizziness, lightheadedness, fainting, and fatigue[2].

People with POTS often experience a drop in blood pressure when standing, along with the increased heart rate. Researchers are studying whether REGN7544’s ability to block NPR1 might help stabilize blood pressure and reduce heart rate increases when POTS patients stand up[2].

Clinical Trials Overview

REGN7544 is currently being studied in several clinical trials to evaluate its safety, effectiveness, and how it works in the body. Here’s an overview of the current trials:

Phase 1 Trial in Healthy Volunteers

A Phase 1 trial is testing REGN7544 in healthy adults to evaluate its safety, tolerability, and how the drug behaves in the body. This study is using a “single ascending dose” approach, meaning participants receive a single dose of the medication that increases for each new group of participants to find a safe dosage range[3].

This trial is examining:

  • Potential side effects
  • How the drug affects blood pressure measurements
  • How much of the drug remains in the blood over time
  • Whether the body develops antibodies against the drug

Phase 2 Trial for Sepsis-Induced Hypotension

This trial is studying REGN7544 in adult patients (ages 18-85) who are hospitalized with sepsis and experiencing low blood pressure requiring vasopressor medications. The main goal is to see if REGN7544 can reduce the total amount of vasopressor medications needed to maintain adequate blood pressure[1].

The study is measuring:

  • Cumulative vasopressor dose over 72 hours
  • Changes in mean arterial pressure (a measure of blood pressure)
  • How quickly patients can be weaned off vasopressors
  • Fluid balance and urine output
  • Safety and side effects

Phase 2 Trial for POTS

This trial is testing a single dose of REGN7544 in patients with POTS to see how it affects heart rate and blood pressure when changing from a lying to standing position[2].

The primary focus is on:

  • Change in heart rate from lying down to standing
  • Effects on blood pressure in different positions
  • Safety and side effects
  • How long the drug stays in the body

Administration Methods

Based on the clinical trial information, REGN7544 can be administered in two different ways[3]:

  1. Intravenous (IV) administration: The medication is injected directly into a vein. This method allows the drug to enter the bloodstream immediately and is being tested in some of the clinical trials.
  2. Subcutaneous (SC) administration: The medication is injected just under the skin. This method is also being tested and may be more convenient for certain applications if the drug eventually becomes approved.

The method of administration may affect how quickly the drug works and how long it stays in the body. The ongoing trials are studying both methods to determine which might be most appropriate for different conditions[3].

Potential Benefits

While REGN7544 is still experimental and its benefits are not yet proven, researchers are investigating several potential advantages this medication might offer[1][2]:

For Sepsis-Induced Hypotension:

  • Possible reduction in the amount of vasopressor medications needed, which could mean fewer side effects from these powerful drugs
  • Potential improvement in blood pressure stability
  • Possible improvements in fluid balance and kidney function (as measured by urine output)

For POTS:

  • Potential reduction in the heart rate increase that occurs when standing
  • Possible improvement in blood pressure regulation when changing positions
  • Potential reduction in symptoms like dizziness and lightheadedness (though this is not directly stated in the trial descriptions)

Safety and Side Effects

Since REGN7544 is still in clinical trials, the full profile of possible side effects is not yet known. The current trials are specifically designed to collect information about safety and side effects[1][2][3].

The trials are monitoring:

  • Treatment-emergent adverse events (TEAEs): These are unwanted medical events that occur after receiving the study drug
  • The severity of any side effects
  • Changes in vital signs including blood pressure, heart rate, and other measurements
  • Development of anti-drug antibodies (ADAs): These are antibodies that the body might create against REGN7544, which could potentially make the drug less effective or cause immune reactions

As with any monoclonal antibody medication, potential concerns could include allergic reactions, injection site reactions, and immune system effects. However, the specific side effect profile of REGN7544 will become clearer as the clinical trials progress[3].

Current Research Status

REGN7544 is currently in Phase 1 and Phase 2 clinical trials. This means that the drug is still in the relatively early stages of human testing[1][2][3]:

  • Phase 1 (in healthy volunteers): Focuses primarily on safety, how the drug moves through the body, and finding appropriate dosages
  • Phase 2 (in patients with the target conditions): Begins to examine effectiveness while continuing to monitor safety

If the results from these trials are promising, REGN7544 would likely need to undergo Phase 3 trials (larger studies in more patients) before it could be considered for approval by regulatory agencies like the FDA or EMA for regular patient use.

It’s important to understand that not all drugs that enter clinical trials ultimately receive approval. The current studies will help determine whether REGN7544 is safe and effective enough to progress further in the development process[1][2][3].

Trial Focus Patient Population Administration Method Primary Outcomes Measured Trial Phase
Sepsis-Induced Hypotension Adults (18-85 years) hospitalized with sepsis and low blood pressure Not specified in source data Cumulative vasopressor dose through 72 hours Phase 2
Postural Orthostatic Tachycardia Syndrome (POTS) Adult patients with POTS Subcutaneous (SC) injection Change in heart rate from supine to standing position Phase 2
Healthy Volunteer Study Healthy adults Both intravenous (IV) and subcutaneous (SC) injection Incidence and severity of side effects through approximately day 162 Phase 1
Common Secondary Outcomes Across Trials: Blood pressure measurements, drug concentration in blood over time, immune response to the drug (anti-drug antibodies)
Trial Design Features: All trials are randomized, double-blind, and placebo-controlled to ensure reliable results

FAQ

  • What conditions is REGN7544 being tested for in clinical trials? REGN7544 is currently being tested in clinical trials for three main conditions: sepsis-induced hypotension (low blood pressure caused by serious infection), Postural Orthostatic Tachycardia Syndrome (POTS), and in healthy volunteers to establish safety and dosing information. The drug targets the NPR1 receptor and may help regulate blood pressure in these different conditions.
  • How is REGN7544 administered to patients? Based on the clinical trial information, REGN7544 can be administered in two ways: intravenously (IV) directly into the bloodstream or subcutaneously (SC) as an injection under the skin. The method of administration varies depending on the specific trial and condition being studied.
  • What are researchers measuring to determine if REGN7544 is effective? Researchers are measuring different outcomes depending on the condition. For sepsis-induced hypotension, they're tracking blood pressure changes, cumulative vasopressor dose (medication needed to raise blood pressure), and fluid balance. For POTS, they're primarily measuring changes in heart rate when moving from lying to standing position. In all trials, they're carefully monitoring safety by tracking side effects.
  • How long do the clinical trials for REGN7544 typically last? The duration varies by trial. The sepsis trial measures outcomes through 72 hours after administration. The POTS study tracks participants for about a month (29 days). The healthy volunteer study has the longest monitoring period, following participants for approximately 162 days to thoroughly assess safety and how the drug moves through the body over time.
  • What is special about how REGN7544 works in the body? REGN7544 is a monoclonal antibody that specifically targets and blocks NPR1 (Natriuretic Peptide Receptor 1), which plays an important role in regulating blood pressure. By antagonizing (blocking) this receptor, REGN7544 may help increase blood pressure in conditions where it's too low (like sepsis) or help normalize cardiovascular responses in conditions like POTS. The trials are designed to better understand exactly how this mechanism works in different patient populations.

Ongoing Clinical Trials on REGN7544

  • Study of REGN7544 for Treating Adults with Low Blood Pressure Caused by Sepsis

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Antagonist Monoclonal Antibody: A laboratory-made protein designed to bind to a specific target in the body (in this case NPR1) and block its normal function. Monoclonal means all the antibodies are identical copies made from a single parent cell.
  • NPR1 (Natriuretic Peptide Receptor 1): A protein receptor in the body that responds to natriuretic peptides, which are hormones that help regulate blood pressure, fluid balance, and cardiovascular function.
  • Sepsis: A potentially life-threatening condition caused by the body's extreme response to an infection, which can lead to tissue damage, organ failure, and death if not treated promptly.
  • Sepsis-Induced Hypotension: Abnormally low blood pressure caused by sepsis, which can reduce blood flow to vital organs and lead to organ damage if not treated.
  • Vasopressors: Medications that constrict (tighten) blood vessels and raise blood pressure. These are commonly used in emergency and intensive care settings to treat severely low blood pressure.
  • POTS (Postural Orthostatic Tachycardia Syndrome): A condition characterized by an abnormal increase in heart rate that occurs after standing up. This can cause dizziness, fainting, and other symptoms due to reduced blood flow to the brain.
  • Pharmacokinetics: The study of how drugs move through the body, including how they're absorbed, distributed, metabolized, and eliminated.
  • Pharmacodynamics: The study of how drugs affect the body and their mechanisms of action, including the relationship between drug concentration and effect.
  • Mean Arterial Pressure (MAP): A measurement of the average pressure in a person's arteries during one cardiac cycle. It's an important indicator of how well organs are being supplied with blood.
  • Intravenous (IV): Administration of a substance directly into a vein, allowing it to enter the bloodstream immediately.
  • Subcutaneous (SC): Administration of a substance beneath the skin, which allows for slower absorption into the bloodstream compared to IV administration.
  • Anti-Drug Antibodies (ADA): Proteins produced by the immune system that recognize and bind to a therapeutic drug, potentially reducing its effectiveness or causing side effects.
  • Double-Blind: A study design where neither the participants nor the researchers know who is receiving the experimental drug versus placebo until after the trial is completed.
  • Placebo-Controlled: A study that compares the effects of an experimental treatment to an inactive substance (placebo) to determine if the treatment has a real effect.
  • Treatment-Emergent Adverse Events (TEAEs): Side effects or unwanted symptoms that appear or worsen after treatment has begun in a clinical trial.
  • Randomized: A process used in clinical trials where participants are assigned by chance to different treatment groups, which helps reduce bias in the research.
  • Phase 1 Trial: The first stage of clinical testing for a new drug, primarily focused on safety, appropriate dosage, and side effects in a small group of people.
  • Phase 2 Trial: The second stage of clinical testing, which further evaluates safety and begins to assess how well the drug works for a specific medical condition in a larger group of patients.

References

  1. https://clinicaltrials.eu/trial/study-of-regn7544-for-treating-adults-with-low-blood-pressure-caused-by-sepsis/
  2. https://clinicaltrials.gov/study/NCT06593600
  3. https://clinicaltrials.gov/study/NCT05970718